First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion

IJU Case Reports

article

Kazunori Shojo¹  Takeo Kosaka¹  Kohei Nakamura²  Hiroshi Hongo¹  Hiroaki Kobayashi¹  Shuji Mikami³  Hiroshi Nishihara²  Mototsugu Oya¹ 

[1] Department of Urology, Keio University School of Medicine;Genomics Unit, Keio Cancer Center, Keio University School of Medicine;Division of Diagnostic Pathology, Keio University Hospital

关键词: ductal adenocarcinoma of the prostate;    MAP3K1;    next-generation sequencing;    prostate cancer;    TP53;   

DOI  :  10.1002/iju5.12274

学科分类：社会科学、人文和艺术（综合）

来源: Wiley

【 摘 要 】

Introduction Ductal adenocarcinoma of the prostate is a rare prostate cancer variant and associated with higher stage and greater risk of mortality. Optimal systemic therapy for metastatic ductal adenocarcinoma is not known. Case presentation A 67-year-old man presented with ductal adenocarcinoma of the prostate accompanied by multiple lung metastases and advanced bone metastases. We performed channel transurethral resection of the prostate and confirmed the diagnosis of ductal adenocarcinoma of the prostate. DNA sequencing identified a TP53 somatic point mutation (p.Gly245Ser) as the pathogenic variant. Furthermore, a homozygous deletion was observed in mitogen-activated protein kinase kinase kinase 1. The patient received enzalutamide but deceased 5 months after presenting to our institution. Conclusion To our knowledge, this is the first report of ductal adenocarcinoma of the prostate with a mitogen-activated protein kinase kinase kinase 1 homozygous deletion. Accumulation of whole-exome sequencing data is expected to inform future advances in therapy development.

【 授权许可】

CC BY|CC BY-NC|CC BY-NC-ND